Pendulum Glucose Control review
The rare supplement whose ad copy matches its trial — A1c −0.6% in a published RCT, from a formula that says outright it is not for weight loss
Reviewed August 26, 2026 · Visit pendulumlife.com
What this is: a dietary supplement — not an FDA-approved medicine. It has not been evaluated by the FDA for safety, efficacy or quality, and nothing in this review is medical advice or an endorsement. If you are considering stopping or replacing prescribed medication with any product on this page, talk to your clinician first.
Overview
What Pendulum Glucose Control is
Pendulum Glucose Control makes the most explicit GLP-1 mechanism claim in this entire registry — a labelled graphic stating the formula increases GLP-1 via butyrate-stimulated gut cells — and it is also the only product here whose headline numbers come from a published randomized controlled trial of the actual formula: multicenter, double-blind, placebo-controlled, in metformin-treated type 2 diabetes, reporting A1c −0.6% and post-meal glucose spikes down about a third. The alignment between claim and evidence is genuinely unusual. The caveats are equally concrete: it is one proof-of-concept-sized trial (n=76), every listed author was a Pendulum employee or shareholder, the label ships 2 billion AFU against a trial formulation described differently, and the company itself states the product is not intended for weight loss and should be used under physician supervision.
Active ingredients
| Ingredient | Published dose |
|---|---|
| Five-strain blend incl. Akkermansia muciniphila, Clostridium butyricum, Anaerobutyricum hallii | 2 billion AFU per serving |
Best for
Adults with type 2 diabetes working with a physician who want the one probiotic with published glycemic RCT data — priced and scoped accordingly.
Limitations
This is a glycemic adjunct, not a weight-loss product — the label says so itself. Anyone buying it for GLP-1-drug-like effects is misreading both the marketing and the science it rests on.
Evidence rating
Peer-reviewed RCTs
Randomized, controlled human trials exist for this ingredient. Read the notes — trial design and sample size matter.
Claims vs evidence
What the brand says, and what we could verify
The company's mechanism claim is quoted or closely paraphrased from its own site. Of 3 cited studies, we could independently confirm 3 in indexed literature.
The claim
'The first probiotic clinically shown to lower A1C and blood glucose spikes'; mechanism graphic states butyrate stimulates gut cells to produce GLP-1, 'a key hormone for controlling blood sugar'. Footnote: this product is not intended for weight loss. Usage note: use only under physician supervision as part of a diabetes management plan.
The evidence
We verified the anchor trial on PubMed: Perraudeau et al., BMJ Open Diabetes Research & Care 2020 — multicenter double-blind RCT, n=76 metformin users with type 2 diabetes, 12 weeks, glucose AUC −36 mg/dL·min and A1c −0.6% versus placebo. The authors themselves called for larger confirming trials, and all held Pendulum equity. Independent strain-level RCTs (pasteurized Akkermansia in Nature Medicine 2019; metabolic-syndrome work with GLP-1-production endpoints in Gut Microbes 2026) support the underlying biology without testing this capsule directly.
| Cited study | Reported finding | Independently verified |
|---|---|---|
| Perraudeau et al., BMJ Open Diabetes Res Care 2020 (PMID 32675291) | Multicenter DBRPC trial, n=76 T2D: glucose AUC −36 mg/dL/180 min (p=0.05); A1c −0.6% | Confirmed on PubMed |
| Depommier et al., Nat Med 2019;25:1096-1103 | Pasteurized A. muciniphila proof-of-concept RCT in overweight adults | Confirmed on PubMed |
| Suenaert et al., Gut Microbes 2026;18:2690689 | RCT with insulin-sensitivity and GLP-1 production endpoints in metabolic syndrome | Confirmed on PubMed |
Facts
Regulation, testing, dosing and price
Every figure is published by the brand. Where something is not disclosed, we say so rather than estimating.
- Regulatory status
- A dietary supplement making disease-management-adjacent claims — an acknowledged gray zone. The brand positions it as a 'medical probiotic' for nutritional management of type 2 diabetes and routes FSA/HSA reimbursement through a letter-of-medical-necessity questionnaire. No warning-letter match surfaced in recent FDA exports.
- Third-party testing
- Manufactured in Pendulum's own oxygen-free U.S. cGMP facility
- Acid-resistant capsule delivery
- No named external certifier captured
- How it's taken
- Two capsules daily, refrigerated; use an opened bottle within two months.
- Safety disclosures
- Transient digestive changes expected initially; explicit physician-supervision statement; perishable-handling warnings apply.
- Manufacturer
- Pendulum Therapeutics
- Subscription
- $99 per 30 days on membership (advertised 43% off; welcome offer $79.20)
- Guarantee
- 90-day conditional guarantee: full refund minus shipping if A1C has not dropped after 90 days' use as directed
- Price as published
- One-time purchase (monthly)$139.00
- Three-month supply$267.00 ($89/mo)
Assessment
Pros and cons
Editorial judgment applied to the published facts above.
Pros
- Headline efficacy figures trace to a verifiable randomized controlled trial of this formula
- Explicit GLP-1 mechanism claim paired with honest scope limits ('not for weight loss')
- Physician-supervision framing appropriate to its glycemic ambitions
- Outcome-conditioned 90-day refund aligns company incentives with results
Cons
- Single n=76 proof-of-concept trial authored entirely by company-affiliated researchers
- Label potency (2B AFU) does not map transparently onto the trial formulation
- $99–$139/month approaches prescription copay territory
- Disease-management positioning invites regulatory scrutiny supplements rarely survive
Alternatives
If Pendulum Glucose Control isn't what you're after
Seed DS-01 Daily Synbiotic
Genuinely randomized human trials behind a synbiotic that never mentions GLP-1 — the category borrowed it, not the brand
Peer-reviewed RCTsThorne Berberine
Dozens of real RCTs exist for berberine — and meta-analyses disagree about whether they add up to meaningful weight loss
Peer-reviewed RCTsPendulum Glucose Control: frequently asked questions
Does Pendulum Glucose Control increase GLP-1?
Can it replace metformin or other diabetes medication?
How strong is the evidence?
Sources
Verified August 26, 2026. Supplement formulations and prices change frequently — confirm current details with the brand.
Medical disclaimer
This review is editorial research about a commercial service. It is not medical advice, and it is not a recommendation to start, stop or change any treatment. GLP-1 medications are prescription drugs with real contraindications and side effects. Decisions about whether they are appropriate for you belong with a qualified clinician who knows your medical history. Prices and terms in this category change frequently — we publish the date each review was verified and link every source, but you should confirm current details with the provider before purchasing.